WallStSmart
IOVA

Iovance Biotherapeutics Inc

NASDAQ: IOVA · HEALTHCARE · BIOTECHNOLOGY

$3.36
+1.51% today

Updated 2026-04-30

Market cap
$1.41B
P/E ratio
P/S ratio
5.36x
EPS (TTM)
$-1.09
Dividend yield
52W range
$2 – $6
Volume
17.4M

Iovance Biotherapeutics Inc (IOVA) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
-0.3%
Last 4 quarters
Revenue YoY growth
+17.7%
Most recent quarter
EPS YoY growth
+30.8%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+9.0%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+27.1%
2025-11-06
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2025-12-31$-0.18-2.0%$2.77$2.52-9.0%
2025-11-06$-0.25+4.5%$1.81$2.30+27.1%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.18$-0.18-2.0%$86.77M+17.7%
2025-09-30$-0.26$-0.25+4.5%$67.45M+15.2%
2025-06-30$-0.28$-0.33-17.9%$59.95M+92.7%
2025-03-31$-0.42$-0.36+14.3%$49.32M+6798.5%
2024-12-31$-0.27$-0.26+2.8%$73.69M+15189.2%
2024-09-30$-0.30$-0.28+6.7%$58.55M+12384.9%
2024-06-30$-0.35$-0.34+2.9%$31.11M+12969.7%
2024-03-31$-0.42$-0.42+0.0%$715000.00
2023-12-31$-0.43$-0.45-4.7%$482000.00
2023-09-30$-0.45$-0.46-2.2%$469000.00
2023-06-30$-0.80$-0.47+41.3%$238000.00
2023-03-31$-0.74$-0.50+32.4%

Frequently asked questions

Has Iovance Biotherapeutics Inc beaten earnings estimates?
Iovance Biotherapeutics Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of -0.3% over the last 4 quarters.
How does IOVA stock react to earnings?
IOVA stock has moved an average of +9.0% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Iovance Biotherapeutics Inc's revenue growth rate?
Iovance Biotherapeutics Inc reported year-over-year revenue growth of +17.7% in its most recent quarter, with EPS growing +30.8% year-over-year.